Spyre Therapeutics (SYRE) Stock Forecast & Price Target

$27.83 +0.02 (+0.07%)

(As of 11/26/2024 ET)

Spyre Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 10 Analyst Ratings

Sell
0

Hold
0

Buy
10

Based on 10 Wall Street analysts who have issued ratings for Spyre Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 10 analysts, 10 have given a buy rating for SYRE.

Consensus Price Target

$48.57
74.53% Upside

According to the 10 analysts' twelve-month price targets for Spyre Therapeutics, the average price target is $48.57. The highest price target for SYRE is $65.00, while the lowest price target for SYRE is $31.00. The average price target represents a forecasted upside of 74.53% from the current price of $27.83.

Get the Latest News and Ratings for SYRE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Spyre Therapeutics and its competitors.

SYRE Analyst Ratings Over Time

Type	Current Forecast 11/27/23 to 11/26/24	1 Month Ago 10/28/23 to 10/27/24	3 Months Ago 8/29/23 to 8/28/24	1 Year Ago 11/27/22 to 11/27/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	10 Buy rating(s)	10 Buy rating(s)	9 Buy rating(s)	N/A
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$48.57	$46.43	$43.17	N/A
Forecasted Upside	74.53% Upside	33.38% Upside	54.00% Upside	N/A
Consensus Rating	Buy	Buy	Buy	N/A

This Crisis Could Be Worse Than 2008 (Ad)

Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America is teetering on the edge of a collapse unlike anything we've seen.

In my new book, "Midnight in America," I expose the hidden deals between Washington and Wall Street.

SYRE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SYRE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Spyre Therapeutics Stock vs. The Competition

Type	Spyre Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	74.53% Upside	25,213.02% Upside	6.71% Upside
News Sentiment Rating	Neutral News See Recent SYRE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/13/2024	Robert W. Baird 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$50.00 ➝ $65.00	+81.46%
11/8/2024	Wedbush 4 of 5 stars		Reiterated Rating	Outperform	$45.00	+13.71%
10/25/2024	Guggenheim 2 of 5 stars		Boost Target	Buy ➝ Buy	$50.00 ➝ $65.00	+85.50%
7/16/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/13/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$35.00 ➝ $40.00	+5.62%
5/10/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$32.00 ➝ $40.00	+5.18%
3/26/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$36.00 ➝ $54.00	+40.33%
12/11/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$31.00	+58.08%
12/4/2023	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Slutsky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
11/29/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:30 PM ET.

SYRE Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Spyre Therapeutics is $48.57, with a high forecast of $65.00 and a low forecast of $31.00.
: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spyre Therapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SYRE shares.
: According to analysts, Spyre Therapeutics's stock has a predicted upside of 74.53% based on their 12-month stock forecasts.
: Spyre Therapeutics has been rated by research analysts at Guggenheim, Robert W. Baird, and Wedbush in the past 90 days.
: Analysts like Spyre Therapeutics more than other "medical" companies. The consensus rating for Spyre Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SYRE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This Crisis Could Be Worse Than 2008 (Ad)

Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America is teetering on the edge of a collapse unlike anything we've seen.

In my new book, "Midnight in America," I expose the hidden deals between Washington and Wall Street.

This page (NASDAQ:SYRE) was last updated on 11/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spyre Therapeutics (SYRE) Stock Forecast & Price Target